The WHO Global Gonococcal Antimicrobial Surveillance Programme (WHO GASP), monitors trends in drug-resistant gonorrhoea. According to WHO GASP data, 97% of countries that reported data between 2009 to 2014, found strains that are resistant to ciprofloxacin, a next-level antibiotics developed in the mid 2000s. The data also cite increasing resistance to other drugs, including the current last-resort treatment, Cefixime (oral) or Ceftriaxone (injectable).
As a result, WHO issued updated global treatment recommendations in 2016 advising doctors to give 2 antibiotics: ceftriaxone and azithromycin.
“Any new treatment developed should be accessible to everyone who needs it, while ensuring it’s used appropriately, so that drug resistance is slowed as much as possible.” – Dr Manica Balasegaram, GARDP Director.
There are currently 3 new candidate drugs in various stages of development: solithromycin, for which a phase III trial has recently been completed; zoliflodacin, which has completed a phase II trial; and gepotidacin, which has also completed a phase II trial.
For full statement – http://who.int/mediacentre/news/releases/2017/Antibiotic-resistant-gonorrhoea/en/